PFA Audited (Consolidated & Standalone) Financial Results for the Quarter and Year Ended 31st March 2025 pursuant to Regulation 33 of SEBI (LODR).
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Midcap 150 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma has submitted its audited financial results for the fourth quarter and full financial year ended 31st March 2025, covering both consolidated and standalone numbers, as required under SEBI's Listing Obligations and Disclosure Requirements. This is a routine regulatory filing that makes the company's full-year and quarterly performance publicly available to investors. The actual financial figures (revenue, profit, margins, etc.) are contained in the attached results document but are not reproduced in the headline. Investors should review the detailed results for year-on-year comparisons and segment-wise performance.
As a standard quarterly and annual results disclosure, this filing itself does not directly move the stock price — the market reaction will depend on how the actual numbers compare with street estimates and prior-year figures. Shareholders should compare the reported revenue, profit after tax, and margin trends against consensus expectations.